AbbVie acquired Mitokinin, a biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson’s Disease (PD), for $110 million at closing and up to $545 million upon the achievement of certain development and commercial milestones, plus royalties on sales. Mitokinin’s lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson’s disease pathoge...